Alnylam Pharma (ALNY) Announces Sanofi Genzyme Will Opt-in to co-Develop, co-Commercialize Fitusiran in Hemophilia, Rare Bleeding Disorders
Go back to Alnylam Pharma (ALNY) Announces Sanofi Genzyme Will Opt-in to co-Develop, co-Commercialize Fitusiran in Hemophilia, Rare Bleeding Disorders| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 146.07 +0.28 (0.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $145.79 | 52 Week High | $109.10 | |||
| Open | $147.35 | 52 Week Low | $31.38 | |||
| Day High | $150.27 | P/E | N/A | |||
| Day Low | $145.04 | EPS | $-1.45 | |||
| Volume | 543,726 | |||||
| SANOFI (NASDAQ: SNY) | Delayed: 47.69 +0.54 (1.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $47.15 | 52 Week High | $44.76 | |||
| Open | $47.07 | 52 Week Low | $36.81 | |||
| Day High | $48.38 | P/E | N/A | |||
| Day Low | $47.00 | EPS | $0.00 | |||
| Volume | 1,664,860 | |||||
